A security alliance shaping the future of connected infrastructure

Tern plc

Device Authority’s KeyScaler platform has built its reputation on automating device identity at scale. Rather than relying on manual oversight, the system creates, rotates and retires digital identities across vast fleets of connected assets. For investors, the attraction is clear: this reduces exposure to breaches that often trace back to unmanaged or outdated credentials. But automation alone is only part of the equation. To be effective, these capabilities must be embedded into complex corporate ecosystems, which is where Optiv’s advisory strength comes into play.

The shift toward Zero Trust frameworks has sharpened the spotlight on machine identities. Unlike perimeter-based security, Zero Trust requires constant validation of every entity on the network. Device Authority’s identity-first approach fits directly into this narrative, while Optiv brings the experience needed to operationalise it for clients that span critical sectors such as energy, healthcare and manufacturing. The synergy points to a model where cyber defences are not bolted on as an afterthought but are woven into the operational fabric from the outset.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search